<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03240822</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00027539</org_study_id>
    <nct_id>NCT03240822</nct_id>
  </id_info>
  <brief_title>Human Penile Tissue Allotransplantation for Devastating Penile and Concomitant Genital Trauma</brief_title>
  <official_title>Vascularized Composite Allotransplantation (VCA) for Devastating Penile and Concomitant Genital Trauma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 4-year, non-randomized, single center, patient self-controlled, clinical trial&#xD;
      (though enrolled subjects will be followed for life as are all transplant patients) for&#xD;
      patients seeking allotransplantation of the male external genitalia (MEG), or penile tissue,&#xD;
      as a feasible reconstructive strategy for the treatment of devastating and irreversible&#xD;
      injuries to the genitalia. In addition to receiving penile allotransplantation and&#xD;
      post-operative monitoring and support, enrolled patients will receive an innovative and&#xD;
      clinically proven immunomodulatory protocol that combines lymphocyte depletion of the&#xD;
      recipient with donor bone marrow cell infusion. Patients will be treated with lymphocyte&#xD;
      depleting induction therapy, donor bone marrow cell infusion and tacrolimus. After the first&#xD;
      year, maintenance immunosuppression will be modified gradually and cautiously (tapered dose&#xD;
      reduction or spaced frequency dosing of tacrolimus) in selected patients based on a critical&#xD;
      evaluation of clinical and immunologic outcomes. Outcomes will include but not be limited to&#xD;
      functional metrics (sensation, erection, voiding), psychosocial (body integrity, adaptation&#xD;
      to transplant) and health related quality of life (HRQOL) measures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initial treatment with an antibody targeting recipient immune cells followed by triple-drug&#xD;
      maintenance therapy represents the current standard in clinical VCA. Our protocol is&#xD;
      different from the existing conventional drug treatments used in MEG allotransplantation in&#xD;
      that it combines donor bone marrow infusion with an immunosuppression sparing protocol. The&#xD;
      primary goal of this pilot clinical trial is to determine the feasibility of using allogeneic&#xD;
      penile tissue to repair/replace irreversibly damaged external genitalia. Enrolled and&#xD;
      transplanted subjects will be followed for their lifetime as a transplant patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of Funding&#xD;
  </why_stopped>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All subjects receive transplant and immunosuppression therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for Immunosuppressive drug therapy</measure>
    <time_frame>6 months</time_frame>
    <description>The amount of immunosuppressive drug therapy will be recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>erectile function</measure>
    <time_frame>6 months</time_frame>
    <description>This will be assessed following intracorporal injection of vaso-active agents, such as prostaglandin, phentolamine, papaverine, or some mixture of these drugs (i.e. Trimix). and through high-resolution duplex Doppler ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of sensory return and sensory thresholds</measure>
    <time_frame>6 months</time_frame>
    <description>This will be accomplished by penile biothesiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of hemodynamic status</measure>
    <time_frame>6 months</time_frame>
    <description>Dynamic infusion pharmaco-cavernosometry and cavernosography will be utilized to better understand these changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Reintegration to Normal Living (RNL) Index</measure>
    <time_frame>6 months</time_frame>
    <description>The RNL is an 11-item questionnaire that asks how a person manages activities, roles, and relationships on a day-to-day basis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Situational Inventory of Body-Image Dysphoria (SIBID)</measure>
    <time_frame>6 months</time_frame>
    <description>The SIBID is a multidimensional body-image survey assessment of people's negative body-image emotions in everyday situations and physical experiences.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Function and Body Image Survey</measure>
    <time_frame>6 months</time_frame>
    <description>This survey consists of six open-ended questions regarding personal thoughts, opinions, and experiences about the transplant, and the individual's current functional abilities.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Urologic Injuries</condition>
  <condition>Genital Diseases, Male</condition>
  <condition>Amputation</condition>
  <arm_group>
    <arm_group_label>Penile Allotransplant and Immunosuppression Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Penile transplantation with monoclonal antibody induction therapy of humanized anti CD52 followed by donor bone marrow infusion and tacrolimus monotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Penile Transplant</intervention_name>
    <description>Penile Allotransplantation</description>
    <arm_group_label>Penile Allotransplant and Immunosuppression Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Monoclonal Antibody (Humanized Anti-CD52)</intervention_name>
    <arm_group_label>Penile Allotransplant and Immunosuppression Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <arm_group_label>Penile Allotransplant and Immunosuppression Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: For Recipients&#xD;
&#xD;
          1. Male&#xD;
&#xD;
          2. 18-40 years&#xD;
&#xD;
          3. Irreversible and devastating genitalia damage not amenable to conventional&#xD;
             reconstruction.&#xD;
&#xD;
          4. Patent main vessels leading into the remaining penile stump, as confirmed by&#xD;
             angiography.&#xD;
&#xD;
          5. Adequate penile stump (&gt; 2.5cm) to facilitate placement of a tourniquet, debridement&#xD;
             of the distal portion and sufficient distal mobilization of the structures requiring&#xD;
             anastomosis&#xD;
&#xD;
          6. Eligible for long term standard of care coverage&#xD;
&#xD;
        Exclusion Criteria: For Recipients&#xD;
&#xD;
          1. Documented history of:&#xD;
&#xD;
               1. cancer&#xD;
&#xD;
               2. renal impairment&#xD;
&#xD;
               3. hepatic disorders&#xD;
&#xD;
               4. neurologic disorders (sensory or motor function deficits)&#xD;
&#xD;
               5. severe scarring with poor host tissue bed&#xD;
&#xD;
               6. penile resection or implant surgery&#xD;
&#xD;
               7. diabetes&#xD;
&#xD;
               8. hypertension&#xD;
&#xD;
               9. hyperlipidemia&#xD;
&#xD;
              10. coronary artery disease&#xD;
&#xD;
              11. untreated genital cancer&#xD;
&#xD;
              12. HIV, Hepatitis B or C, or any infectious disease&#xD;
&#xD;
              13. erectile dysfunction&#xD;
&#xD;
              14. Peyronie's disease&#xD;
&#xD;
              15. urethral stricture disease&#xD;
&#xD;
              16. balanitis&#xD;
&#xD;
              17. xerotica obliterans&#xD;
&#xD;
              18. pelvic embolization&#xD;
&#xD;
              19. pelvic radiation&#xD;
&#xD;
              20. untreated hypogonadism&#xD;
&#xD;
              21. prior prostate surgery&#xD;
&#xD;
              22. recurrent urinary tract infections (UTIs)&#xD;
&#xD;
              23. nephrolithiasis&#xD;
&#xD;
              24. connective tissue disease or collagen disease&#xD;
&#xD;
              25. lipopolysaccharidosis or amyloidosis&#xD;
&#xD;
          2. Use of 5-alpha-reductase inhibitors&#xD;
&#xD;
          3. External signs, sequelae or positive serology of sexually transmitted disease&#xD;
             (including HPV)&#xD;
&#xD;
          4. Active UTI, stones, urethral edema and other pathology that prevents urethral&#xD;
             anastomosis&#xD;
&#xD;
          5. Current or past substance abuse&#xD;
&#xD;
          6. Current or past smoker (within past 3 months)&#xD;
&#xD;
          7. Use of any medications known to cause vasoconstriction&#xD;
&#xD;
          8. Psychiatric illness or psychological problems, or deemed unsuitable on psychiatric&#xD;
             evaluation&#xD;
&#xD;
          9. Any condition that may prevent transplantation (positive cross match, high panel&#xD;
             reactive antibody (PRA), etc.)&#xD;
&#xD;
         10. Uncontrolled bleeding disorder, platelet count &gt; 50,000, hemophilia or any other&#xD;
             inherited coagulopathy or need to routinely receive blood products for bleeding&#xD;
             disorders&#xD;
&#xD;
         11. Concurrent participation in any other clinical investigation during the period of this&#xD;
             investigation&#xD;
&#xD;
         12. Inability to undergo leukapheresis&#xD;
&#xD;
         13. Inability to participate in all necessary study activities due to physical or mental&#xD;
             limitations&#xD;
&#xD;
         14. Inability or unwillingness to return for all required follow-up visits.&#xD;
&#xD;
         15. Inability or unwillingness to sign the patient informed consent document.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>This is a male, penile transplantation study.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Atala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 2, 2017</study_first_submitted>
  <study_first_submitted_qc>August 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2017</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Penile Trauma</keyword>
  <keyword>Allotransplantation</keyword>
  <keyword>Vascularized Composite Allotransplantation</keyword>
  <keyword>VCA</keyword>
  <keyword>Genital Trauma</keyword>
  <keyword>Penile Transplantation</keyword>
  <keyword>Amputation</keyword>
  <keyword>Penile Injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

